| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 16th March 2020 | Carl Goldfischer | 690,232 | Conversion of derivative | $0.00 | |
| 16th March 2020 | Carl Goldfischer | 13,148 | Conversion of derivative | $0.00 | |
| 10th October 2019 | Sujal Shah | 5,000 | Open or private purchase | $4.30 | $21,500.00 |
| 23rd September 2019 | Sujal Shah | 3,100 | Open or private purchase | $5.55 | $17,205.00 |
| 20th September 2019 | Sujal Shah | 1,900 | Open or private purchase | $5.50 | $10,450.00 |
| 7th February 2019 | Carl Goldfischer | 2,335 | Exercise of derivative | $5.00 | $11,675.00 |
| 7th February 2019 | Carl Goldfischer | 9,340 | Exercise of derivative | $5.50 | $51,370.00 |
| 7th February 2019 | Carl Goldfischer | 11,675 | Open or private sale | $9.02 | $105,328.35 |
Cyma Bay Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company. Its products include MBX-8025 and Arhalofenate. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Ticker: CBAY
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1042074
Employees: 43
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $188 Th for the period Apr 2020 to Jun 2020 in the context of all up
Restructuring Charges of $117 Th for the period Jan 2020 to Jun 2020 in the context of all up
Restructuring Charges of $48 M for the period Jan 2020 to Jun 2020 in the context of Prepaid research and development costs
Fundamentals
Cash at Carrying Value: $96 M (286%)
Assets, Current: $174 M (-14%)
Property, Plant and Equipment, Net: $2 M (-13%)
Other Assets, Noncurrent: $160 Th (0%)
Assets: $177 M (-14%)
Accounts Payable, Current: $476 Th (-80%)
Liabilities, Current: $9 M (-46%)
Liabilities: $11 M (-43%)
Common Stock, Value, Issued: $7 Th (0%)
Common Stock, Shares, Issued: $69 M (0%)
Retained Earnings (Accumulated Deficit): $650 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $186 Th (132%)
Stockholders' Equity (Parent): $166 M (0%)
Liabilities and Equity: $177 M (-14%)
Research and Development: $8 M (-54%)
General and Administrative Expenses: $3 M (-56%)
Restructuring Charges: $188 Th (60%)
Operating Income/Loss: $11 M (-55%)
Other Income, net: $426 Th (-66%)
EPS (basic): $0.16 (0%)
EPS (diluted): $0.16 (0%)
News
HP to pay US$6 million fine to settle SEC charges
30th September 2020
NextEra Energy CEO rules out hostile M&A after offer to Duke Energy
30th September 2020
Alphabet Inc's Google launches Google TV, new Chromecast
30th September 2020
Meet the lawyers behind the upcoming US/Google antitrust showdown
30th September 2020